Preferences help
enabled [disable] Abstract
Number of results
2018 | 5 | 2 | 65-74
Article title

Miejsce angiografii fluoresceinowej wśród współczesnych badań obrazowych w okulistyce – część I

Title variants
The position of fluorescein angiography among modern imaging techniques in ophthalmology – part I
Languages of publication
Angiografia fluoresceinowa siatkówki jest jednym z najstarszych badań obrazowych w okulistyce. Wraz z wprowadzeniem optycznej koherentnej tomografii do codziennej praktyki klinicznej zmieniły się również wskazania do wykonywania angiografii fluoresceinowej. W prezentowanej pracy omówiono współczesne zastosowania angiografii fluoresceinowej w diagnostyce schorzeń siatkówki oraz wymieniono główne wskazania do jej wykonania. Badanie to jest porównywane z optyczną koherentną tomografią oraz angiografią OCT. Autor wskazuje także główne kierunki rozwoju techniki angiograficznej.
Fluorescein angiography is one of the oldest forms of imaging in ophthalmology. However, with the advent of optical coherence tomography in everyday clinical practice, indications for performing fluorescein angiography have significantly changed. In the following paper, modern application of fluorescein angiography in diagnostics of retinal diseases has been outlined as well as main recommendations for its performance. It has been compared with optical coherence tomography and OCT angiography. Author presents main directions for development of this technique.
Physical description
  • Poradnia Okulistyczna Dobry Wzrok w Gdańsku; Oddział Okulistyczny, Szpital Specjalistyczny im. J.K. Łukowicza w Chojnicach
  • 1. Docchio F. Ocular fluorometry: principles, fluorophores, instrumentation, and clinical applications. Lasers Surg Med 1989; 9(6): 515- -532.
  • 2. Delori FC, Castany MA, Webb RH. Fluorescence characteristics of sodium fluorescein in plasma and whole blood. Exp Eye Res 1978; 27(4): 417-425.
  • 3. Delori F, Ben-Sira I, Trempe C. Fluorescein angiography with an optimized filter combination. Am J Ophthalmol 1976; 82(4): 559-566.
  • 4. Morykwas MJ, Hills H, Argenta LC. The safety of intravenous fluorescein administration. Ann Plast Surg 1991; 26(6): 551-553.
  • 5. Halperin LS, Olk RJ, Soubrane G, et al. Safety of fluorescein angiography during pregnancy. Am J Ophthalmol 1990; 109(5): 563-566.
  • 6. Nielsen NV. The normal retinal fluorescein angiogram I. A study of the fluoresceinangiographic appearance of the retina in normal subjects without ophthalmoscopically obvious pathological changes. Acta Ophthalmol (Copenh) 1982; 60(5): 657-670.
  • 7. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237(4): 185-222.
  • 8. Ito S, Miyamoto N, Ishida K, et al. Association between external limiting membrane status and visual acuity in diabetic macular oedema. Br J Ophthalmol 2013; 97(2): 228-232.
  • 9. Maheshwary AS, Oster SF, Yuson RM, et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 2010; 150(1): 63-67.
  • 10. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 2014; 132(11): 1309-1316.
  • 11. Radwan SH, Soliman AZ, Tokarev J, et al. Association of Disorganization of Retinal Inner Layers With Vision After Resolution of Center-Involved Diabetic Macular Edema. JAMA Ophthalmol 2015; 133(7): 820-825.
  • 12. Grewal DS, O’Sullivan ML, Kron M, et al. Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular Edema. Am J Ophthalmol 2017; 177: 116-125.
  • 13. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 807-822.
  • 14. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 834-840.
  • 15. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94(7): 761-774.
  • 16. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995; 113(9): 1144-1155.
  • 17. Conrath J, Valat O, Giorgi R, et al. Semi-automated detection of the foveal avascular zone in fluorescein angiograms in diabetes mellitus. Clin Exp Ophthalmol 2006; 34(2): 119-123.
  • 18. Inoue M, Azumi A, Shirabe H, et al. Iridopathy in eyes with proliferative diabetic retinopathy: detection of early stage of rubeosis iridis. Ophthalmologica 1998; 212(1): 15-18.
  • 19. Holz FG, Bellmann C, Margaritidis M, et al. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999; 237(2): 145-152
  • 20. Holz FG, Bellman C, Staudt S, et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42(5): 1051-1056.
  • 21. Leys A, Vanrenterghem Y, Van Damme B, et al. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol 1991; 229(5): 406-410.
  • 22. van de Ven JP, Boon CJ, Fauser S, et al. Clinical evaluation of 3 families with basal laminar drusen caused by novel mutations in the complement factor H gene. Arch Ophthalmol 2012; 130(8): 1038-1047.
  • 23. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119(2): 198-207.
  • 24. Azab M, Boyer DS, Bressler NM, et al; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123(4): 448-457.
  • 25. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131(5): 541-560.
  • 26. Grunwald JE, Daniel E, Ying GS, et al; CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2012; 119(8): 1634-1641.
  • 27. Heimes B, Lommatzsch A, Zeimer M, et al. [Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]. Ophthalmologe 2011; 108(2): 124-131.
  • 28. Milani P, Massacesi A, Moschini S, et al. Multimodal imaging and diagnosis of myopic choroidal neovascularization in Caucasians. Clin Ophthalmol 2016; 10: 1749-1757.
  • 29. Lee DH, Kang HG, Lee SC, et al. Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography. Br J Ophthalmol 2018; 102(2): 238-242.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.